i have alot of shares guys and love the company. Whats your

New Post Public Reply Private Reply Replies (2) Message Board
stockplayer

i have alot of shares guys and love the company. Whats your guys take on this post on ihub he is really respected on ihub just curious thanks

Shares issued to Ironridge at 70% of the market price plus processing fees equal to 11% of the amount borrowed from Ironridge is a better funding deal than most other short term toxic penny stock financing deals?

Hardly.

It is still a very toxic deal that amounts to hundreds of millions of super discounted free trading stock and high interest rates (in this case processing fees).


Ironridge is still due approximately $519,643.74 from the first round of $643,134 in financing they provided and that is after already receiving 143,500,000 shares towards that debt. That means a few hundred million more free trading shares of RFMK stock will get issued to Ironridge to get dumped into the market.

When Ironridge finishes dumping their 143,500,000 free trading shares they got on September 19th and comes calling for their next big round of shares they are going to want the RFMK share price to be as low as possible so that they will have more opportunity for profits. Just like they want the share price to be as high as possible while they are selling their shares. It is all about profiting as much as possible for Ironridge. That means the biggest part of the Ironridge dumping will happen right before they put in their request for their next round of approximately 145,000,000+ free trading shares.

Their financing agreement prevents them from shorting RFMK to drive the price down, but it doesn't prevent them from using heaving dumping on the back end to position the share price for them to get more RFMK shares for their money for the next round of dumping.

This is a must read post about how the financing deal works

http://investorshub.advfn.com/boards/read_msg...d=80277315


Ironridge cannot provide $2.2 million in financing without doing an S-1 filing. The Form D 504 exemption only covers up to $1,000,000 in financing. Since $195,000 of that financing was already used up before the Ironridge deal that means the most RFMK will be able to borrow from Ironridge is $805,000. That is actually good news for the RFMK shareholders because bottom line is that this is a very toxic financing agreement that will cause hundreds of millions of shares to be diluted into the market (possibly over 1 billion shares if the full $805,000 is borrowed).

That makes the latest PR about $2.2 in funding mostly just hype to help pump the share price. Just like the 10K that will never happen (all hype to pump the share price).


I'm curious what makes the Ironridge/RFMK 504 offering any different than the toxic 504 offerings that TJ Management and Fairhills used to get discounted free trading stock in pink sheet companies that recently landed them in SEC litigation (links below)

http://www.sec.gov/news/press/2012/2012-165.htm

http://sec.gov/litigation/complaints/2012/com...12-165.pdf

http://www.sec.gov/litigation/complaints/2012/comp22452.pdf

Fact is that it isn't any different. It is illegal.


Here is a great article published by an experienced SEC attorney that explains why 504 stock is almost never legally free trading.

http://www.securitieslawyer101.com/the-rule-504-myth/

Rapid Fire Marketing, Inc. (RFMK) Stock Research Links

RFMK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Your Rights as a Humacyte, Inc. Investor

Updated Category News Views 110

Understanding Your Rights as a Humacyte, Inc. Investor Humacyte, Inc. (NASDAQ: HUMA) has recently captured the attention of investors due to certain legal developments affecting its share value. If you are a shareholder who purchased shares during the specific class period of May 10, 2024, to October 17, 2024, you may want to take active steps to protect your investment...

Continue Reading
Jim Chanos Raises Concerns About Oracle's Accounting Issues

Updated Category News Views 552

Chanos Questions Oracle's Accounting Practices Notable short-seller Jim Chanos has recently highlighted some serious concerns regarding Oracle Corp's accounting integrity. He has voiced skepticism about the company's massive project backlog, especially a significant $300 billion deal partnered with OpenAI, emphasizing that its operational realization is years away and...

Continue Reading
Cyrus Biotechnology Advances Novel IgG Therapy with No Antibodies

Updated Category News Views 171

Promising Developments by Cyrus Biotechnology Cyrus Biotechnology, Inc. has unveiled groundbreaking data showcasing the effectiveness of its engineered IgG-degrading enzyme, CYR241, in a unique rabbit redosing model. This enzyme demonstrates significant therapeutic activity without the formation of anti-drug antibodies (ADAs) upon repeated administration. Understanding...

Continue Reading
GreenPower Motor Company: Strengthening Its Financial Future

Updated Category News Views 241

GreenPower Motor Company Secures New Term Loan Funding GreenPower Motor Company Inc. (NASDAQ: GP), an innovator in the production and distribution of all-electric medium and heavy-duty vehicles, recently completed the closing of the fifth tranche of its secured term loan offering. This strategic move aims to bolster its operational capabilities, particularly in the cargo,...

Continue Reading
Unlocking the Future: Insights into the Cloud Industry 2025

Updated Category News Views 226

The Promising Future of the Global Cloud Industry The global cloud industry is on a fast track to remarkable growth. Recent research indicates that the market is poised to expand from approximately USD 1,091.4 billion in one year to an impressive USD 1,256.8 billion by 2025. This represents a noteworthy year-over-year increase of about 15.1%. With such staggering figures,...

Continue Reading